Antibody-peptide inhibitor conjugates: A new path for cancer therapy
Cancer treatments often struggle with balancing efficacy and side effects. A new study by EPFL scientists offers a promising solution using antibody-peptide inhibitor conjugates to target specific cell types and block the activity of cancer-promoting enzymes called cathepsins. Tumor cells often hijack normal physiological processes to support their growth, exploiting proteins that are in charge …